ESC Congress 2026: Early statins after T2D diagnosis tied to lower dementia risk

Clinical takeaway: Consider starting a statin at T2D diagnosis rather than deferring; earlier initiation was associated with a larger reduction in dementia risk. 

Patients with type 2 diabetes carry a higher risk of dementia than their peers. With few treatment options, prevention should be the focus. But the question for clinicians has been which levers actually move that risk and when to pull them. Elevated LDL cholesterol is one candidate: it runs high in T2D, and detecting and treating it from midlife is among the modifiable risk factors highlighted by the Lancet Commission on dementia prevention. 

Statins are already indicated for cardiovascular protection in these patients, yet they remain underused in T2D. Whether the timing of statin initiation matters for cognitive outcomes has been an open question. A nationwide Danish analysis designed to emulate a randomized trial now suggests it might, and that the answer favors starting early. 

Over a median 7.1 years of follow-up, 2.7% of the cohort developed dementia. Patients who started a statin within a year of diagnosis had a 15% lower relative risk of dementia at 10 years than those who started none within five years, with the range running from 9% to 21% lower. In absolute terms the gap was 0.59 percentage points, or roughly six fewer dementia cases per 1,000 patients. 

Starting between one and five years after diagnosis was tied to a 10% lower relative risk, a range of 3% to 15%, and an absolute difference of 0.38 percentage points, about four fewer cases per 1,000. The pattern ran stepwise: dementia risk was highest with no statin therapy, lower with late initiation, and lowest with early initiation. Associations were similar in women and men. 

The analysis drew on Danish national registers to identify 132,585 statin-naïve adults who developed type 2 diabetes from 2006 through 2019, with follow-up until dementia, death, emigration, or the end of 2021. A clone-censor-weight design emulating a target trial compared three strategies: no statin within five years of diagnosis as the reference, initiation within one year, and initiation between one and five years. The primary outcome was 10-year risk of all-cause dementia. 

LDL-C is on the Lancet Commission's list of modifiable dementia risk factors, and this analysis adds timing as a possibly consequential variable within one of the most accessible interventions on that list. Commission modeling suggests nearly half of dementia cases could theoretically be prevented by eliminating 14 such risk factors. For now, the authors' argument is narrower: patients with T2D and high LDL-C already have a cardiovascular indication for statins, and these data suggest the cognitive stakes of deferring may not be zero. 

"People with type 2 diabetes already have a higher risk of dementia and are advised to lower cholesterol to reduce their risk of heart attack and stroke. This study suggests that starting statins soon after a type 2 diabetes diagnosis may also be linked to a modest reduction in dementia risk, with greater benefit than delaying treatment," said Isabel Goncalves, professor of cardiology at Lund University, Sweden, and a member of the ESC Communication Committee. 

Source: Ternhamar T, et al. (2026 Aug 30) Lancet Reg Health Eur. Association between timing of statin treatment after diabetes diagnosis and risk of dementia: a nationwide observational study